Update on emerging drug therapies for systemic lupus erythematosus

Bibliography

• Mok CC. Emerging drug therapies for systemic lupus erythematosus. Expert Opin Emerg Drugs 2006;11:597-608
   PubMedGoogle Scholar
• Mok CC. Accelerated atherosclerosis, arterial thromboembolism, and preventive strategies in systemic lupus erythematosus. Scand J Rheumatol 2006;35:85-95
   PubMed Web of Science ®Google Scholar
• Mok CC, Wong RWS, Lai KN. Treatment of severe proliferative lupus nephritis: the current state. Ann Rheum Dis 2003;62:799-804
   PubMed Web of Science ®Google Scholar
• American College of Rheumatology nomenclature and case definitions for neuropsychiatric lupus syndromes. Arthritis Rheum 1999;42:599-608
   PubMed Web of Science ®Google Scholar
• Neuwelt CM, Lacks S, Kaye BR, Role of intravenous cyclophosphamide in the treatment of severe neuropsychiatric systemic lupus erythematosus. Am J Med 1995;98:32-41
   PubMed Web of Science ®Google Scholar
• Barile-Fabris L, Ariza-Andraca R, Olguín-Ortega L, Controlled clinical trial of IV cyclophosphamide versus IV methylprednisolone in severe neurological manifestations in systemic lupus erythematosus. Ann Rheum Dis 2005;64:620-5
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RWS. Treatment of lupus psychosis with oral cyclophosphamide followed by azathioprine maintenance: an open study. Am J Med 2003;115:59-62
   PubMed Web of Science ®Google Scholar
• Mok CC. Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006;36:71-81
   PubMed Web of Science ®Google Scholar
• Mok CC. Update on the therapies of severe lupus nephritis. Curr Rheumatol Rev 2006;2:186-90
   Google Scholar
• Mok CC, Lau CS. Pathogenesis of SLE. J Clin Pathol 2003;56:481-90
   PubMed Web of Science ®Google Scholar
• Kirou KA, Salmon JE, Crow MK. Soluble mediators as therapeutic targets in systemic lupus erythematosus: cytokines, immunoglobulin receptors, and the complement system. Rheum Dis Clin North Am 2006;32:103-19
   PubMed Web of Science ®Google Scholar
• Austin HA III, Klippel JH, Balow JE, Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med 1986;314:614-9
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Austin HA III, Vaughn EM, Controlled trial of pulse methylprednisolone versus two regimens of pulse cyclophosphamide in severe lupus nephritis. Lancet 1992;340:741-5
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho CT, Chan KW, Outcome and prognostic indicators of diffuse proliferative lupus glomerulonephritis treated with sequential oral cyclophosphamide and azathioprine. Arthritis Rheum 2002;46:1003-13
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, Long-term outcome of patients with diffuse proliferative lupus nephritis treated with prednisolone and oral cyclophosphamide followed by azathioprine. Lupus 2005;14:265-72
   PubMed Web of Science ®Google Scholar
• Mok CC, Lau CS, Wong RWS. Risk factors for ovarian failure in patients with systemic lupus erythematosus receiving cyclophosphamide therapy. Arthritis Rheum 1998;41:831-7
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. Arthritis Rheum 2004;50:3934-40
   PubMed Web of Science ®Google Scholar
• Houssiau FA, Vasconcelos C, D'Cruz D, The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose versus high-dose intravenous cyclophosphamide. Ann Rheum Dis 2009. [Epub ahead of print]
   Web of Science ®Google Scholar
• Mok CC, Lai KN. Mycophenolate mofetil in lupus glomerulonephritis. Am J Kidney Dis 2002;40:447-57
   PubMed Web of Science ®Google Scholar
• Mak A, Mok CC. Mycophenolate mofetil for refractory haemolytic anemia in systemic lupus erythematosus. Lupus 2005;14:856-8
   PubMed Web of Science ®Google Scholar
• Schanz S, Ulmer A, Rassner G, Fierlbeck G. Successful treatment of subacute cutaneous lupus erythematosus with mycophenolate mofetil. Br J Dermatol 2002;147:174-8
   PubMed Web of Science ®Google Scholar
• Glicklich D, Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998;32:318-22
   PubMed Web of Science ®Google Scholar
• Buratti S, Szer IS, Spencer CH, Mycophenolate mofetil treatment of severe renal disease in pediatric onset systemic lupus erythematosus. J Rheumatol 2001;28:2103-8
   PubMed Web of Science ®Google Scholar
• Dooley MA, Cosio FG, Nachman PH, Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999;10:833-9
   PubMed Web of Science ®Google Scholar
• Karim MY, Pisoni CN, Ferro L, Reduction of proteinuria with mycophenolate mofetil in predominantly membranous lupus nephropathy. Rheumatology (Oxford) 2005;44:1317-21
   PubMed Web of Science ®Google Scholar
• Kapitsinou PP, Boletis JN, Skopouli FN, Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004;43:377-80
   PubMed Web of Science ®Google Scholar
• Spetie DN, Tang Y, Rovin BH, Mycophenolate therapy of SLE membranous nephropathy. Kidney Int 2004;66:2411-15
   PubMed Web of Science ®Google Scholar
• Kasitanon N, Petri M, Haas M, Mycophenolate mofetil as the primary treatment of membranous lupus nephritis with and without concurrent proliferative disease: a retrospective study of 29 cases. Lupus 2008;17:40-5
   PubMed Web of Science ®Google Scholar
• Chan TM, Li FK, Tang CS, Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62
   PubMed Web of Science ®Google Scholar
• Chan TM, Tse KC, Tang CS, ; Hong Kong Nephrology Study Group. Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis. J Am Soc Nephrol 2005;16:1076-84
   PubMed Web of Science ®Google Scholar
• Ginzler EM, Dooley MA, Aranow C, Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. New Engl J Med 2005;353:2219-28
   PubMed Web of Science ®Google Scholar
• Appel GB, Contreras G, Dooley MA, ; Aspreva Lupus Management Study Group. Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 2009;20:1103-12
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Tang S, Predictors and outcome of renal flares after successful cyclophosphamide treatment for diffuse proliferative lupus glomerulonephritis. Arthritis Rheum 2004;50:2559-68
   PubMed Web of Science ®Google Scholar
• Mok CC, Ying KY, Ng WL, Long-term outcome of diffuse proliferative lupus glomerulonephritis treated with cyclophosphamide. Am J Med 2006;119:355.e25-33
   PubMed Web of Science ®Google Scholar
• Contreras G, Pardo V, Leclercq B, Sequential therapies for proliferative lupus nephritis. N Engl J Med 2004;350:971-80
   PubMed Web of Science ®Google Scholar
• Houssiau FA, D'Cruz DP, Sangle SR, Azathioprine versus mycophenolate mofetil for maintenance immunosuppression of proliferative lupus nephritis [abstract 1150]. 2009 ACR/ARHP Annual Meeting; 18 – 21 October 2009
   Google Scholar
• Politt D, Heintz B, Floege J, Mertens PR. Tacrolimus- (FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004;62:49-53
   PubMed Web of Science ®Google Scholar
• Mok CC, Tong KH, To CH, Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005;68:813-7
   PubMed Web of Science ®Google Scholar
• Mok CC, Ho CT, Siu YP, Treatment of diffuse proliferative lupus glomerulonephritis: a comparison of two cyclophosphamide-containing regimens. Am J Kidney Dis 2001;38:256-64
   PubMed Web of Science ®Google Scholar
• Szeto CC, Kwan BC, Lai FM, Tacrolimus for the treatment of systemic lupus erythematosus with pure class V nephritis. Rheumatology (Oxford) 2008;47:1678-81
   PubMed Web of Science ®Google Scholar
• Mok CC, Tong KH, Siu YP, Tacrolimus versus mycophenolate mofetil for induction treatment of severe lupus nephritis: a randomized controlled trial. Ann Rheum Dis 2007;66(Suppl II):473
   Google Scholar
• Fernandez DR, Telarico T, Bonilla E, Activation of mammalian target of rapamycin controls the loss of TCRzeta in lupus T cells through HRES-1/Rab4-regulated lysosomal degradation. J Immunol 2009;182:2063-73
   PubMed Web of Science ®Google Scholar
• Wu P, Wu J, Liu S, TLR9/TLR7-triggered downregulation of BDCA2 expression on human plasmacytoid dendritic cells from healthy individuals and lupus patients. Clin Immunol 2008;129:40-8
   PubMed Web of Science ®Google Scholar
• Ramos-Barrón A, Piñera-Haces C, Gómez-Alamillo C, Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus 2007;16:775-81
   PubMed Web of Science ®Google Scholar
• Lui SL, Yung S, Tsang R, Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus 2008;17:305-13
   PubMed Web of Science ®Google Scholar
• Fernandez D, Bonilla E, Mirza N, Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum 2006;54:2983-8
   PubMed Web of Science ®Google Scholar
• Medina F, Fuentes J, Carranza I, Sirolimus: a potential treatment for diffuse proliferative lupus nephritis. Ann Rheum Dis 2006;65(Suppl II):351
   Google Scholar
• Krishnan S, Juang YT, Chowdhury B, Differential expression and molecular associations of Syk in systemic lupus erythematosus T cells. J Immunol 2008;181:8145-52
   PubMed Web of Science ®Google Scholar
• Bahjat FR, Pine PR, Reitsma A, An orally bioavailable spleen tyrosine kinase inhibitor delays disease progression and prolongs survival in murine lupus. Arthritis Rheum 2008;58:1433-44
   PubMed Web of Science ®Google Scholar
• Remer CF, Weisman MH, Wallace DJ. Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study. Lupus 2001;10:480-3
   PubMed Web of Science ®Google Scholar
• Petera P, Mander B, Manger K, A pilot study of leflunomide in systemic lupus erythematosus. Arthritis Rheum 2001;48:S241
   Google Scholar
• Tam LS, Li EK, Wong CK, Double-blind, randomized, placebo-controlled pilot study of leflunomide in systemic lupus erythematosus. Lupus 2004;13:601-4
   PubMed Web of Science ®Google Scholar
• Tam LS, Li EK, Wong CK, Safety and efficacy of leflunomide in the treatment of lupus nephritis refractory or intolerant to traditional immunosuppressive therapy: an open-label trial. Ann Rheum Dis 2006;65:417-8
   PubMed Web of Science ®Google Scholar
• Wang HY, Cui TG, Hou FF, ; China Leflunomide Lupus Nephritis Study Group. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multi-centre observational study. Lupus 2008;17:638-44
   PubMed Web of Science ®Google Scholar
• Zhang FS, Nie YK, Jin XM, The efficacy and safety of leflunomide therapy in lupus nephritis by repeat kidney biopsy. Rheumatol Int 2009;29:1331-5
   PubMed Web of Science ®Google Scholar
• Gensburger D, Kawashima M, Marotte H, Lupus erythematosus with leflunomide: induction or reactivation? Ann Rheum Dis 2005;64:153-5
   PubMed Web of Science ®Google Scholar
• Goeb V, Berthelot JM, Joly P, Leflunomide-induced subacute cutaneous lupus erythematosus. Rheumatology (Oxford) 2005;44:823-4
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Engleman EG, McGuire JL. An open study of dehydroepiandrosterone in systemic lupus erythematosus. Arthritis Rheum 1994;37:1305-10
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Engleman EG, McGuire JL. Dehydroepiandrosterone in systemic lupus erythematosus: results of a doubleblind, placebo-controlled, randomized clinical trial. Arthritis Rheum 1995;38:1826-31
   PubMed Web of Science ®Google Scholar
• Petri MA, Lahita RG, Van Vollenhoven RF, ; for the GL701 study group. Effects of prasterone on corticosteroid requirements of women with systemic lupus erythematosus: a double-blind, randomized, placebo-controlled trial. Arthritis Rheum 2002;46:1820-9
   PubMed Web of Science ®Google Scholar
• Chang DM, Lan JL, Lin HY, Luo SF. Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus: a multicenter randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:2924-7
   PubMed Web of Science ®Google Scholar
• Petri MA, Mease PJ, Merrill JT, Effects of prasterone on disease activity and symptoms in women with active systemic lupus erythematosus. Arthritis Rheum 2004;50:2858-68
   PubMed Web of Science ®Google Scholar
• Sánchez-Guerrero J, Fragoso-Loyo HE, Neuwelt CM, Effects of prasterone on bone mineral density in women with active systemic lupus erythematosus receiving chronic glucocorticoid therapy. J Rheumatol 2008;35:1567-75
   PubMed Web of Science ®Google Scholar
• Hartkamp A, Geenen R, Godaert GL, Effects of dehydroepiandrosterone on fatigue and well-being in women with quiescent systemic lupus erythematosus. A randomized controlled trial. Ann Rheum Dis 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Toubi E, Kessel A, Shoenfeld Y. High-dose intravenous immunoglobulins: an option in the treatment of systemic lupus erythematosus. Hum Immunol 2005;66:395-402
   PubMed Web of Science ®Google Scholar
• Zandman-Goddard G, Levy Y, Shoenfeld Y. Intravenous immunoglobulin therapy and systemic lupus erythematosus. Clin Rev Allergy Immunol 2005;29:219-28
   PubMed Web of Science ®Google Scholar
• Boletis JN, Ioannidis JP, Boki KA, Moutsopoulos HM. Intravenous immunoglobulin compared with cyclophosphamide for proliferative lupus nephritis. Lancet 1999;354:569-70
   PubMed Web of Science ®Google Scholar
• Orbach H, Tishler M, Shoenfeld Y. Intravenous immunoglobulin and the kidney--a two-edged sword. Semin Arthritis Rheum 2004;34:593-601
   PubMed Web of Science ®Google Scholar
• Winder A, Molad Y, Ostfeld I, Treatment of systemic lupus erythematosus by prolonged administration of high dose intravenous immunoglobulin: report of 2 cases. J Rheumatol 1993;20:495-8
   PubMed Web of Science ®Google Scholar
• Leandro MJ, Cambridge G, Edwards JC, B-cell depletion in the treatment of patients with systemic lupus erythematosus: a longitudinal analysis of 24 patients. Rheumatology (Oxford) 2005;44:1542-5
   PubMed Web of Science ®Google Scholar
• Marks SD, Patey S, Brogan PA, B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum 2005;52:3168-174
   PubMed Web of Science ®Google Scholar
• Gottenberg JE, Guillevin L, Lambotte O, Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. Ann Rheum Dis 2005;64:913-20
   PubMed Web of Science ®Google Scholar
• van Vollenhoven RF, Gunnarsson I, Welin-Henriksson E, Biopsy-verified response of severe lupus nephritis to treatment with rituximab (anti-CD20 monoclonal antibody) plus cyclophosphamide after biopsy-documented failure to respond to cyclophosphamide alone. Scand J Rheumatol 2004;33:423-7
   PubMed Web of Science ®Google Scholar
• Li EK, Tam LS, Zhu TY, Is combination rituximab with cyclophosphamide better than rituximab alone in the treatment of lupus nephritis? Rheumatology (Oxford) 2009;48:892-8
   PubMed Web of Science ®Google Scholar
• Tamimoto Y, Horiuchi T, Tsukamoto H, A dose-escalation study of rituximab for treatment of systemic lupus erythematosus and Evans' syndrome: immunological analysis of B cells, T cells and cytokines. Rheumatology (Oxford) 2008;47:821-7
   Google Scholar
• Tokunaga M, Saito K, Kawabata D, Efficacy of rituximab (anti-CD20) for refractory systemic lupus erythematosus involving the central nervous system. Ann Rheum Dis 2007;66:470-5
   PubMed Web of Science ®Google Scholar
• Jónsdóttir T, Gunnarsson I, Risselada A, Treatment of refractory SLE with rituximab plus cyclophosphamide: clinical effects, serological changes, and predictors of response. Ann Rheum Dis 2008;67:330-4
   PubMed Web of Science ®Google Scholar
• Melander C, Sallée M, Trolliet P, Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009;4:579-87
   PubMed Web of Science ®Google Scholar
• Gunnarsson I, Sundelin B, Jónsdóttir T, Histopathologic and clinical outcome of rituximab treatment in patients with cyclophosphamide-resistant proliferative lupus nephritis. Arthritis Rheum 2007;56:1263-72
   PubMed Web of Science ®Google Scholar
• Willems M, Haddad E, Niaudet P, ; French Pediatric-Onset SLE Study Group. Rituximab therapy for childhood-onset systemic lupus erythematosus. J Pediatr 2006;148:623-7
   PubMed Web of Science ®Google Scholar
• Vigna-Perez M, Hernández-Castro B, Paredes-Saharopulos O, Clinical and immunological effects of Rituximab in patients with lupus nephritis refractory to conventional therapy: a pilot study. Arthritis Res Ther 2006;8:R83
   PubMed Web of Science ®Google Scholar
• Looney RJ, Anolik JH, Campbell D, B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I/II dose-escalation trial of rituximab. Arthritis Rheum 2004;50:2580-9
   PubMed Web of Science ®Google Scholar
• Lambotte O, Dürbach A, Kotb R, Failure of rituximab to treat a lupus flare-up with nephritis. Clin Nephrol 2005;64:73-7
   PubMed Web of Science ®Google Scholar
• Edelbauer M, Jungraithmayr T, Zimmerhackl LB. Rituximab in childhood systemic lupus erythematosus refractory to conventional immunosuppression: case report. Pediatr Nephrol 2005;20:811-13
   PubMed Web of Science ®Google Scholar
• Anolik JH, Campbell D, Felgar RE, The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum 2003;48:455-9
   PubMed Web of Science ®Google Scholar
• Cambridge G, Isenberg DA, Edwards JC, B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response. Ann Rheum Dis 2008;67:1011-6
   PubMed Web of Science ®Google Scholar
• Albert D, Dunham J, Khan S, Variability in the biological response to anti-CD20 B cell depletion in systemic lupus erythaematosus. Ann Rheum Dis 2008;67:1724-31
   PubMed Web of Science ®Google Scholar
• Anolik JH, Barnard J, Owen T, Delayed memory B cell recovery in peripheral blood and lymphoid tissue in systemic lupus erythematosus after B cell depletion therapy. Arthritis Rheum 2007;56:3044-56
   PubMed Web of Science ®Google Scholar
• Merrill JT, Neuwelt CM, Wallace DJ, Rituximab in extra-renal SLE patients showed no significant difference compared to placebo at 52 weeks in the randomized double-blind phase II/III study EXPLORER. Ann Rheum Dis 2009;68(Suppl3):249
   PubMed Web of Science ®Google Scholar
• Merril JT, Buyon JP, Furie R, Flare assessment in systemic lupus erythematosus (SLE) patients treated with rituximab in the phase II/III EXPLORER Trial [abstract 925]. 2009 ACR/ARHP Annual Meeting; 18 – 21 October 2009
   Google Scholar
• Furie R, Looney RJ, Rovin B, Efficacy and safety of rituximab in subjects with active proliferative lupus nephritis (LN): results from the randomized, double-blind phase III LUNAR Study [abstract 1149]. 2009 ACR/ARHP Annual Meeting; 18 – 21 October 2009
   Google Scholar
• Available from: http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm187791.htm
   Google Scholar
• A study to evaluate two doses of ocrelizumab in patients with active systemic lupus erythematosus (BEGIN). Available from: www.clinicaltrials.gov/ct2/show/NCT00539838 (2009)
   Google Scholar
• A study to evaluate ocrelizumab in patients with nephritis due to systemic lupus erythematosus (BELONG). Available from: www.clinicaltrials.gov/ct2/show/NCT00626197 (2009)
   Google Scholar
• Dörner T, Kaufmann J, Wegener WA, Initial clinical trial of epratuzumab (humanized anti-CD22 antibody) for immunotherapy of systemic lupus erythematosus. Arthritis Res Ther 2006;8:R74
   PubMed Web of Science ®Google Scholar
• Furie R, Stohl W, Ginzler EM, Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008;10:R109
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Stohl W, Furie RA, A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009;61:1168-78
   PubMed Web of Science ®Google Scholar
• Petri MA, Furie R, Merrill J, Four-year experience of belimumab, a BLyS-specific inhibitor, in systemic lupus erythematosus patients [abstract 2069]. 2009 ACR/ARHP Annual Meeting; 18 – 21 October 2009
   Google Scholar
• Navarra S, Guzman R, Gallacher A, Belimumab, a BLyS-Specific inhibitor, reduced disease activity, flares and prednisone use in patients with active SLE: efficacy and safety results from the phase 3 BLISS-52 Study [abstract LB1]. 2009 ACR/ARHP Annual Meeting; 18 – 21 October 2009
   Google Scholar
• Gatto B. Atacicept, a homodimeric fusion protein for the potential treatment of diseases triggered by plasma cells. Curr Opin Investig Drugs 2008;9:1216-27
   PubMed Web of Science ®Google Scholar
• Dall'Era M, Chakravarty E, Wallace D, Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007;56:4142-50
   PubMed Web of Science ®Google Scholar
• Pena-Rossi C, Nasonov E, Stanislav M, An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus. Lupus 2009;18:547-55
   PubMed Web of Science ®Google Scholar
• Furie RA, Cash JM, Cronin ME, Treatment of systemic lupus erythematosus with LJP 394. J Rheumatol 2001;28:257-65
   PubMed Web of Science ®Google Scholar
• Alarcón-Segovia D, Tumlin JA, Furie RA, LJP 394 for the prevention of renal flare in patients with systemic lupus erythematosus: results from a randomized, double-blind, placebo-controlled study. Arthritis Rheum 2003;48:442-54
   PubMed Web of Science ®Google Scholar
• Cardiel MH, Tumlin JA, Furie RA, ; LJP 394-90-09 Investigator Consortium. Abetimus sodium for renal flare in systemic lupus erythematosus: results of a randomized, controlled phase III trial. Arthritis Rheum 2008;58:2470-80
   PubMed Web of Science ®Google Scholar
• Study of LJP 394 in lupus patients with history of renal disease (ASPEN). Available from: www.clinicaltrials.gov/ct2/show/NCT00089804 (2009)
   Google Scholar
• Finck BK, Linsley PS, Wofsy D. Treatment of murine lupus with CTLA4Ig. Science 1994;265:1225-7
   PubMed Web of Science ®Google Scholar
• Daikh DI, Wofsy D. Cutting edge: reversal of murine lupus nephritis with CTLA4Ig and cyclophosphamide. J Immunol 2001;166:2913-6
   PubMed Web of Science ®Google Scholar
• Merill JT, Burgos-Vargas R, Westhovens R, Activity of Abatacept in SLE: results of a 12-month phase II exploratory study. Ann Rheum Dis 2009;68(Suppl 3):70
   Google Scholar
• Daikh DI, Finck BK, Linsley PS, Long-term inhibition of murine lupus by brief simultaneous blockade of the B7/CD28 and CD40/gp39 costimulation pathways. J Immunol 1997;159:3104-8
   PubMed Web of Science ®Google Scholar
• Davis JC Jr, Totoritis MC, Rosenberg J, Phase I clinical trial of a monoclonal antibody against CD40-ligand (IDEC-131) in patients with systemic lupus erythematosus. J Rheumatol 2001;28:95-101
   PubMed Web of Science ®Google Scholar
• Kalunian KC, Davis JC Jr, Merrill JT, ; IDEC-131 Lupus Study Group. Treatment of systemic lupus erythematosus by inhibition of T cell costimulation with anti-CD154: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:3251-8
   PubMed Web of Science ®Google Scholar
• Boumpas DT, Furie R, Manzi S, ; BG9588 Lupus nephritis trial group. A short course of BG9588 (anti-CD40 ligand antibody) improves serologic activity and decreases hematuria in patients with proliferative lupus glomerulonephritis. Arthritis Rheum 2003;48:719-27
   PubMed Web of Science ®Google Scholar
• Sthoeger ZM, Sharabi A, Dayan M, The tolerogenic peptide, hCDR1, down-regulates pathogenic cytokines and apoptosis and up-regulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients. Hum Immunol 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Sharabi A, Zinger H, Zborowsky M, A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta. Proc Natl Acad Sci USA 2006;103:8810-5
   PubMed Web of Science ®Google Scholar
• Pego-Reigosa JM, Isenberg DA. Systemic lupus erythematosus: pharmacological developments and recommendations for a therapeutic strategy. Expert Opin Investig Drugs 2008;17:31-41
   PubMed Web of Science ®Google Scholar
• Ishida H, Muchamuel T, Sakaguchi S, Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/W F1 mice. J Exp Med 1994;179:305-10
   PubMed Web of Science ®Google Scholar
• Llorente L, Richaud-Patin Y, García-Padilla C, Clinical and biological effects of anti-interleukin-10 monoclonal antibody administration in systemic lupus erythematosus. Arthritis Rheum 2000;43:1790-800
   PubMed Web of Science ®Google Scholar
• Aringer M, Graninger WB, Steiner G, Smolen JS. Safety and efficacy of tumor necrosis factor alpha blockade in systemic lupus erythematosus: an open-label study. Arthritis Rheum 2004;50:3161-9
   PubMed Web of Science ®Google Scholar
• Aringer M, Houssiau F, Gordon C, Adverse events and efficacy of TNF-alpha blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology (Oxford) 2009;48:1451-4
   PubMed Web of Science ®Google Scholar
• Linker-Israeli M, Deans RJ, Wallace DJ, Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis. J Immunol 1991;147:117-23
   PubMed Web of Science ®Google Scholar
• Finck BK, Chan B, Wofsy D. Interleukin 6 promotes murine lupus in NZB/NZW F1 mice. J Clin Invest 1994;94:585-91
   PubMed Web of Science ®Google Scholar
• Mihara M, Takagi N, Takeda Y, Ohsugi Y. IL-6 receptor blockage inhibits the onset of autoimmune kidney disease in NZB/W F1 mice. Clin Exp Immunol 1998;112:397-402
   PubMed Web of Science ®Google Scholar
• Wang Y, Hu Q, Madri JA, Amelioration of lupus-like autoimmune disease in NZB/WF1 mice after treatment with a blocking monoclonal antibody specific for complement component C5. Proc Natl Acad Sci USA 1996;93:8563-8
   PubMed Web of Science ®Google Scholar
• Rother RP, Mojcik CF, McCroskery EW. Inhibition of terminal complement: a novel therapeutic approach for the treatment of systemic lupus erythematosus. Lupus 2004;13:328-34
   PubMed Web of Science ®Google Scholar
• Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum. 2006;54:408-20
   PubMed Web of Science ®Google Scholar
• Yao Y, Richman L, Higgs BW, Neutralization of interferon-alpha/beta-inducible genes and downstream effect in a phase I trial of an anti-interferon-alpha monoclonal antibody in systemic lupus erythematosus. Arthritis Rheum 2009;60:1785-96
   PubMed Web of Science ®Google Scholar
• Wallace DJ, Petri MA, Oslen M, MEDI-545, an Anti-Interferon Alpha Monoclonal Antibody, Shows Evidence of Clinical Activity in Systemic Lupus Erythematosus. 2007 ACR abstract [number 1315]
   Google Scholar
• Pavletic SZ, Illei GG. The role of immune ablation and stem cell transplantation in severe SLE. Best Pract Res Clin Rheumatol 2005;19:839-58
   PubMed Web of Science ®Google Scholar
• Burt RK, Traynor A, Statkute L, Nonmyeloablative hematopoietic stem cell transplantation for systemic lupus erythematosus. JAMA 2006;295:527-35
   PubMed Web of Science ®Google Scholar
• Jayne D, Passweg J, Marmont, Autologous stem cell transplantation for systemic lupus erythematosus. Lupus 2004;13:168-76
   PubMed Web of Science ®Google Scholar
• Farge D, Labopin M, Tyndall A, Autologous hematopoietic stem cell transplantation (HSCT) for autoimmune diseases: an observational study on 12 years of experience from the European Group for Blood and Marrow Transplantation (EBMT) Working Party on Autoimmune Diseases. Haematologica 2009. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Daikeler T, Tyndall A. Autoimmunity following haematopoietic stem-cell transplantation. Best Pract Res Clin Haematol 2007;20:349-60
   PubMed Web of Science ®Google Scholar
• Brodsky RA, Petri M, Smith BD, Immunoablative high-dose cyclophosphamide without stem-cell rescue for refractory, severe autoimmune disease. Ann Intern Med 1998;129:1031-5
   PubMed Web of Science ®Google Scholar
• Petri M, Jones RJ, Brodsky RA. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus. Arthritis Rheum 2003;48:166-73
   PubMed Web of Science ®Google Scholar
• Petri M, Brodsky R, Jones R, High-dose cyclophosphamide vs monthly cyclophosphamide: eighteen month results. 2005 ACR abstract [number 1993]
   Google Scholar
• Dussán KB, Magder L, Brodsky RA, High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus 2008;17:1079-85
   PubMed Web of Science ®Google Scholar
• Dazzi F, van Laar JM, Cope A, Tyndall A. Cell therapy for autoimmune diseases. Arthritis Res Ther 2007;9:206
   PubMed Web of Science ®Google Scholar
• Bocelli-Tyndall C, Bracci L, Spagnoli G, Bone marrow mesenchymal stromal cells (BM-MSCs) from healthy donors and auto-immune disease patients reduce the proliferation of autologous- and allogeneic-stimulated lymphocytes in vitro. Rheumatology (Oxford) 2007;46:403-8
   PubMed Web of Science ®Google Scholar
• Toubai T, Paczesny S, Shono Y, Mesenchymal Stem Cells for Treatment and Prevention of Graft-Versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation. Curr Stem Cell Res Ther 2009. [Epub ahead of print]
   PubMedGoogle Scholar
• Le Blanc K, Rasmusson I, Sundberg B, Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004;363:1439-41
   PubMed Web of Science ®Google Scholar
• Sun L, Akiyama K, Zhang H, Mesenchymal stem cell transplantation reverses multiorgan dysfunction in systemic lupus erythematosus mice and humans. Stem Cells 2009;27:1421-32
   PubMed Web of Science ®Google Scholar
• Sutter JA, Kwan-Morley J, Dunham J, A longitudinal analysis of SLE patients treated with rituximab (anti-CD20): factors associated with B lymphocyte recovery. Clin Immunol 2008;126:282-90
   PubMed Web of Science ®Google Scholar